Suspension Vero Cells (Svero) For Poliovirus Production: Effect Of Culture Passage On Growth Kinetics And Productivity,
2012
School of Biochemistry and Biological Sciences Universidad Nacional del Litoral Zelltek S.A.
Suspension Vero Cells (Svero) For Poliovirus Production: Effect Of Culture Passage On Growth Kinetics And Productivity, Guillermina Forno
Vaccine Technology IV
No abstract provided.
Systematically Characterizing Adventitious Agent Tests For Biologics,
2012
National Institute of Allergy & Infectious Diseases
Systematically Characterizing Adventitious Agent Tests For Biologics, Rebecca Sheets
Vaccine Technology IV
No abstract provided.
Automation And Multiplexing Of Immunoassays: Improving Precision And Throughput,
2012
PPD
Automation And Multiplexing Of Immunoassays: Improving Precision And Throughput, Ilia Tikhonov
Vaccine Technology IV
No abstract provided.
Microbial Fermentation: New Tools To Speed-Up Vaccine Antigen Development And Increase Process Knowledge,
2012
Sanofi Pasteur
Microbial Fermentation: New Tools To Speed-Up Vaccine Antigen Development And Increase Process Knowledge, Catherine Jourdat
Vaccine Technology IV
No abstract provided.
Building Pandemic Preparedness Through A Sustainable Enterprise For Influenza Vaccines,
2012
BARDA
Building Pandemic Preparedness Through A Sustainable Enterprise For Influenza Vaccines, Robert Huebner
Vaccine Technology IV
No abstract provided.
High Cell Density Cultivations For Influenza Virus Production Using Suspension Cells,
2012
Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany
High Cell Density Cultivations For Influenza Virus Production Using Suspension Cells, Y. Genzel, T. Vogel, J. Buck, I. Behrendt, G. Schiedner, I. Jordan, U. Reichl
Vaccine Technology IV
No abstract provided.
Rmce-Based Sf9 Cell Factory For Production Of Multi-Meric Vlps,
2012
ITQB-UNL/IBET
Rmce-Based Sf9 Cell Factory For Production Of Multi-Meric Vlps, Ana Teixera
Vaccine Technology IV
No abstract provided.
Bacterial Expression Of A Vlp Sub-Unit For Rapid And Cheap Influenza Vaccination,
2012
Australian Institute for Bioengineering and Nanotechnology The University of Queensland, Australia
Bacterial Expression Of A Vlp Sub-Unit For Rapid And Cheap Influenza Vaccination, Anton Middelberg
Vaccine Technology IV
No abstract provided.
Developing A Suite Of Analytics To Support Process Development For The Manufacture Of Polysaccharides,
2012
Pfizer
Developing A Suite Of Analytics To Support Process Development For The Manufacture Of Polysaccharides, Aaron Noyes, Ranga Godavarti, Nigel Titchener-Hooker, Jonathan Coffman, Tarit Mukhopadhyay
Vaccine Technology IV
No abstract provided.
Cervical Cancer Immunotherapy: Induction Of Hpv Specific Ctls In Human Volunteers After Vgx-3100 Immunization,
2012
Inovio Pharmaceuticals
Cervical Cancer Immunotherapy: Induction Of Hpv Specific Ctls In Human Volunteers After Vgx-3100 Immunization, Niranjan Sardesai
Vaccine Technology IV
No abstract provided.
A Protein-Free Process And Product Protection System,
2012
Stabilitech Ltd., UK
A Protein-Free Process And Product Protection System, Stephen Ward
Vaccine Technology IV
No abstract provided.
Functional Genomics As A Tool To Define A Molecular Signature Of Effective Vaccination Against Foot And Mouth Disease Virus,
2012
Departamento de Desarrollo Biotecnologico, Facultad de Medicina, Universidad de la Republica, Uruguay
Functional Genomics As A Tool To Define A Molecular Signature Of Effective Vaccination Against Foot And Mouth Disease Virus, Jose Chabalgoity
Vaccine Technology IV
No abstract provided.
Oncolytic Viruses As Cancer Therapies,
2012
Mayo Clinic
Oncolytic Viruses As Cancer Therapies, Stephen Rusell
Vaccine Technology IV
No abstract provided.
Chimpanzee Ad Vector Technology Platform For Prophylactic And Therapeutic Genetic Vaccine Applications,
2012
okairos
Chimpanzee Ad Vector Technology Platform For Prophylactic And Therapeutic Genetic Vaccine Applications, Stefano Colloca
Vaccine Technology IV
No abstract provided.
Challenges In Optimizing Formulations For Multi- Antigen Vaccines,
2012
Pfizer Global R&D
Challenges In Optimizing Formulations For Multi- Antigen Vaccines, Lakshmi Khandke
Vaccine Technology IV
No abstract provided.
A New Successful Vaccine Against Babesiosis: Any Use For Malaria?,
2012
Merck
A New Successful Vaccine Against Babesiosis: Any Use For Malaria?, Thep Schetters
Vaccine Technology IV
No abstract provided.
The Cmc Challenges In Developing An Oncolytic Immunotherapy,
2012
Amgen
The Cmc Challenges In Developing An Oncolytic Immunotherapy, Colin Love
Vaccine Technology IV
No abstract provided.
High Throughput Formulation Design For A Stable Lyophilized Virus-Like Particle Vaccine Against Group A Streptococcu,
2012
The University of Queensland
High Throughput Formulation Design For A Stable Lyophilized Virus-Like Particle Vaccine Against Group A Streptococcu, Yap Chuan
Vaccine Technology IV
No abstract provided.
Process Development For A Peptide Conjugated Qbetavirus Like Particle (Vlp) Vaccine,
2012
Pfizer
Process Development For A Peptide Conjugated Qbetavirus Like Particle (Vlp) Vaccine, Jennifer Thorn
Vaccine Technology IV
No abstract provided.
Formulation And Stability Of A Chikungunya Virus-Like Particle (Chikv Vlp) Based Vaccine,
2012
Vaccine Production Program Laboratory National Institutes of Health
Formulation And Stability Of A Chikungunya Virus-Like Particle (Chikv Vlp) Based Vaccine, Rhicard Schwartz
Vaccine Technology IV
No abstract provided.
